BioSpace News Archive

Aldeyra Therapeutics, Inc. today announced that results from the randomized, double-masked, vehicle-controlled, crossover Phase 2 clinical trial of reproxalap in an allergen chamber model have been published in the peer-reviewed journal Clinical Ophthalmology.

Outgoing CEO Gail Garland to consult with OBIO for successful transition of not-for-profit.

Scipher Medicine Announces Publication of Real-World Study Demonstrating Clinical Utility of PrismRA ® Blood Test.

Biosero, Inc. today announced a collaboration with Araceli Biosciences that will allow scientists to integrate Araceli’s Endeavor™ high-speed imaging platform.

iECURE today announced that it has expanded its management team by adding two experienced industry executives into key roles within the organization.

Cyclica Inc. welcomes drug discovery veteran Michael (Mike) Palovich as Chief Science Officer, Head of Drug Discovery.

Cortexyme, Inc. today announced that its board of directors has appointed Christopher Lowe, the company’s chief operating officer and chief financial officer, as interim chief executive.

Acer Therapeutics Inc. announced that Acer’s management team will virtually participate in the BIO CEO & Investor Conference on February 14-17, 2022.

Liver Institute Northwest is enrolling participants into RESPONSE, a global phase 3 clinical research study evaluating the safety and efficacy of seladelpar, an investigational drug for people already diagnosed with PBC who have been using ursodeoxycholic acid (also known as UDCA or ursodiol) but have not achieved the recommended treatment goal or cannot tolerate UDCA.

SELLAS Life Sciences Group, Inc. announced today the completion of enrollment in the Phase 1/2 clinical trial of the Company’s lead asset, galinpepimut-S (GPS), in combination with Merck’s anti-PD-1 therapy, KEYTRUDA®.